Salute e Benessere

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

"Our team is pleased to be among the first to enroll patients in this important study," said Fakhir Elmasri, M.D., Interventional Radiologist, Lakeland Vascular Institute, Lakeland, Florida. "Our first patient presented with complex, bilateral iliac disease and was randomized to treatment with VBX Stent Grafts. I look forward to seeing the results of the study to inform device selection for durable outcomes in the future." "Our team is pleased to be among the first to…

Epitomee® Announces Successful Completion of Pivotal Clinical Trial for…

Notably, the majority of Epitomee® completers achieved, in 24 weeks, between 5% and 15% or greater weight loss. Noteworthy, 27% of participants lost at least 10% of their body weight and 11% achieved a 15% or more weight reduction. Notably, the majority of Epitomee® completers achieved, in 24 weeks, between 5% and 15% or greater weight loss. Noteworthy, 27% of participants lost at least 10% of their body weight and 11% achieved a 15% or more weight reduction. Importantly, the study...

Message from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD

Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024 Dear Shareholders,Happy New Year.I write to update you on our key developments towards precision medicine for healthy longevity - starting with cancer - powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery towards our vision of a world with effective cancer treatments free from toxic chemotherapy.As we move...

Compass Pathways enters into research collaboration agreement with Hackensack…

Health(“HMH”), a leading not-for-profit health care organization and the largest, most comprehensive and truly integrated network in New Jersey, today announced that that they have entered into a research collaboration agreement to inform the delivery model design of investigational COMP360 psilocybin treatment, if FDA-approved. The collaboration between Compass and HMH aims to improve health outcomes and improve patient and provider experiences for mental health conditions such as...

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology…

To register for this event, please reach out to your B. Riley Securities sale representative. The replay of the presentation will be accessible in the “Investors” section of the company's website,https://www.therivabio.com, under “Events.” About Theriva Biologics, Inc.Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new...

Agepha Pharma and Caristo Diagnostics Team Up to Fight Coronary Inflammation

"Caristo shares Agepha Pharma's passion for fighting coronary inflammation, which is one of the primary drivers of heart attack risks," said Frank Cheng, CEO of Caristo Diagnostics. "We look forward to collaborating with Agepha Pharma in order to combat heart disease as the number one cause of death globally." "Caristo shares Agepha Pharma's passion for fighting coronary inflammation, which is one of the primary drivers of heart attack risks," said Frank Cheng, CEO…

Unchained Labs has the inside track on Lentivirus RNA detection, launches new…

Leprechaun lets researchers skip all this pain using a combination of antibody capture, fluorescence, and interferometry to quantify lentiviruses based on their size, surface proteins and structural features that make them work – on up to 16 samples per run and using only 1 – 25 µL. The new RNA application directly measures the percentage of lentiviruses that contain a capsid and are carrying RNA, both on the inside of the virus. For the first time, researchers can measure their intact…

Single Use Support continues to grow, expanding its team by 40%

Innovative process solution provider Single Use Support continues to deliver strong organic growth, supported by an expansion in its employee base. With a successful year 2023 in the rear-view mirror, 2024 is already shaping up to be even better. More than 70% growth of non-COVID business Following strong growth of COVID-related projects in previous years, Single Use Support grew its non-COVID business by more than 70% in 2023. The Austrian-based process solution provider serves the...

EU Deadline for Class D devices draws closer: IMed Consultancy launches new…

The deadline to certify Class D devices under the EU IVDR is around the corner: get ready before 26 May 2025

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents…

Only one antibiotic effective to treat Gonorrhea infectionsOMV based vaccine to prevent Neisseria gonorrhoeae infection BILTHOVEN, The Netherlands, Jan.16, 2024(GLOBE NEWSWIRE) -- Intravacc , a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a funding that may total US$ 633K from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) a global non-profit organisation, for...

Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro…

Geneva, Switzerland, January 16th, 2024– Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million. Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this funding includes a $3.8 million credit facility.The proceeds will be utilized for: (i) preparation of...

UK FACING 'EXHAUSTION EPIDEMIC' New Study by Pro Plus® Reveals 4 in 10 Adults…

Young adults, particularly those aged 18-24 years, are at the forefront of this 'exhaustion epidemic', operating at a mere 43% of their energy potential. Unhealthy eating habits among this age group was reported as a key contributing factor that drained energy, highlighting a need for lifestyle changes. Young adults, particularly those aged 18-24 years, are at the forefront of this 'exhaustion epidemic', operating at a mere 43% of their energy potential. Unhealthy eating habits among this age...

Longer-Term Nut Consumption Improves Brain Insulin Sensitivity, New Study Finds

The trial consisted of 28 healthy men and women aged between 60 and 70 years. The researchers conducted a randomized, single-blinded, crossover study involving a 16-week intervention and control period (no nuts), separated by an 8-week washout period. The intervention consisted of 60 g per day of mixed nuts (15 g each of walnuts, pistachios, cashews, and hazelnuts). Participants were instructed to adhere to the Dutch dietary guidelines. The trial consisted of 28 healthy men and women aged...

ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board

Garching / Munich, Germany, January 16, 2024 –ITM Isotope Technologies Munich SE(ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its Executive Board. Dr. Harfensteller initially joined the ITM Group as Head of Engineering in 2008. He has been appointed as head of production in 2009. Additionally, he became responsible for Research and Development (R&D) in 2011. Since 2016, he has held the position of Chief...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in…

DISCO's pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-specific therapies, with the potential to boost efficacy and reduce side effects for patients. DISCO…

BUILD-A-BEAR UNVEILS DE-LIGHT-FUL "AFTER DARK" COLLECTION WITH A WINK THIS…

Valentine's Day is a perfect time to consider Build-A-Bear for a surprising, unique statement to make your recipient blush over a plush. Start your Valentine's Day shopping early and further customise a gift for your "someone special" by including your own personalised voice message with the Record Your Voice sound chip when building your one-of-a-kind furry friend. Explore After Dark, including these popular items and many more, but warning: there are bears behaving adorably!…

TVM Capital Healthcare invests in Vietnamese Eye Care Business Alina Vision in a…

Alina Vision was founded by international development organisation The Fred Hollows Foundation in 2018. Over the past five years The Fred Hollows Foundation and Rohto Pharmaceutical, a leading eyecare company in Japan, have provided financial backing, eye surgery training and clinical support to Alina Vision to grow the organisation from inception to more than 80 employees across two eye hospitals. Alina Vision was founded by international development organisation The Fred Hollows Foundation in…

Biocomposites expands its international presence by opening new sales and…

Led by Pierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughout Italy. Led byPierluigi Leone, General Manager, the sales team will continue to work with local agents to fulfil tenders and introduce the broader Biocomposites portfolio to surgeons and hospitals throughoutItaly. Pierluigi Leone, Amministratore delegato e General Manager of...

DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its…

"We welcome DRW and Tolmar to DelSiTech as new investors and strategic partners at an important time of growth and development." Said Lasse Leino, Chief Executive Officer at DelSiTech. "This financing marks a significant milestone on our journey as one of the world's leading drug delivery technology providers, with an attractive internal pipeline of controlled release drug products based on Silica Matrix. This investment, together with our increasing revenues from our own drug…

CereCore International Names Andrew Hine as Managing Director

"Andrew's 30-year healthcare background compliments our company's mission," said Curtis Watkins, President and CEO of CereCore International. "He has long seen the need and value that technology can bring to improving workflows, operations, and patient care. His work with the NHS and consulting firms Ernst & Young, KPMG, and most recently Babylon Healthcare will bring the global perspective and business development strategy needed to grow CereCore International."…

Oxford Medical Simulation Raises $12.6 Million in Series A Funding to Address…

OMS is dedicated to training the next generation of nurses, doctors, and allied healthcare professionals. With 91% of graduating nurses feeling unprepared for clinical practice, OMS stands at the forefront of addressing this critical gap, offering immersive training experiences that enable healthcare professionals to practice any place, any time, without risk. This ensures that the first time they encounter a medical emergency, have a difficult conversation or perform a procedure, they...

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic…

More specifically, the STIC CTC trial demonstrates that the use of CTC count as a tool for choosing between endocrine therapy (ET) and chemotherapy (CT) is non-inferior to the investigator's choice in terms of short and long-term clinical outcomes. While approximately 60% of the study participants had a concordant indication between the clinical risk-guided arm and the CTC-guided treatment arm, in the subgroup of patients with a discordant estimate, the use of frontline CT in the CTC-guided…

International Diabetes Federation and Sanofi Global Health Unit collaborate to…

The partnership will enhance the diabetes knowledge and skills of HCPs, particularly primary care physicians, nurses, diabetes educators and pharmacists in 40 countries. The partnership will enhance the diabetes knowledge and skills of HCPs, particularly primary care physicians, nurses, diabetes educators and pharmacists in 40 countries. According to the IDF Diabetes Atlas, the majority of the more than half a billion individuals now living with diabetes worldwide are found in LMICs...

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to…

Gdańsk, Poland – 16 January 2024, 07:00 CET– PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide range of autoimmune diseases, announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The US allowance constitutes an...

Altri Comunicati